TRT and Polycythemia: Managing Elevated Red Blood Cells
Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
Polycythemia, or erythrocytosis, is a common TRT side effect due to increased erythropoietin. Regular HCT monitoring is crucial, with intervention at 50-52% and TRT cessation at 54%. Management includes dose reduction, formulation change, or therapeutic phlebotomy to mitigate cardiovascular risks.
TRT and Polycythemia: Managing Elevated Red Blood Cells
Testosterone Replacement Therapy (TRT) effectively treats hypogonadism, but it's not without potential side effects. One of the most common and clinically significant is polycythemia, specifically erythrocytosis, characterized by an abnormal increase in red blood cell (RBC) mass, hemoglobin, and hematocrit (HCT) [1]. While a modest increase in HCT is expected and often beneficial with TRT, excessive elevation can increase blood viscosity, raising the risk of serious cardiovascular events like stroke, myocardial infarction, and venous thromboembolism [2]. Managing this side effect is crucial for safe and effective TRT.
The Mechanism of TRT-Induced Erythrocytosis
Testosterone stimulates erythropoiesis, the production of red blood cells, primarily by increasing erythropoietin (EPO) secretion from the kidneys. EPO then acts on the bone marrow to produce more RBCs. This effect is dose-dependent and can vary significantly between individuals and different TRT formulations. Injectable testosterone, particularly long-acting esters, is more commonly associated with erythrocytosis than transdermal gels or pellets, likely due to higher peak testosterone levels and fluctuations [3].
Diagnosis and Monitoring
Regular monitoring of hematocrit and hemoglobin levels is essential for all men on TRT. Guidelines recommend checking HCT at baseline, then at 3 and 6 months after initiating TRT, and annually thereafter, or more frequently if levels are rising [4].
- Thresholds: While definitions vary, erythrocytosis is generally diagnosed when hematocrit consistently exceeds 50-52%, with some guidelines recommending intervention at 52% and cessation of TRT if it reaches 54% [1, 5].
- Symptoms: Symptoms of severe erythrocytosis can include headache, dizziness, fatigue, blurred vision, and shortness of breath. However, many men remain asymptomatic until HCT levels are significantly elevated.
- Switching TRT Formulation: Changing from injectable testosterone to a transdermal gel or pellet may reduce erythrocytosis risk due to more stable testosterone levels and lower peak concentrations [3].
- Therapeutic Phlebotomy: This involves the removal of a unit of blood (typically 450-500 mL), similar to blood donation. Phlebotomy directly reduces RBC mass and HCT. It's often performed when HCT exceeds 52% and is repeated as needed to maintain levels below this threshold. While effective, it can lead to iron deficiency and requires ongoing monitoring [6].
- Hydration: Ensuring adequate hydration can help reduce blood viscosity, though it does not directly lower RBC mass.
Management Strategies for Elevated Hematocrit
When HCT levels rise above acceptable thresholds, several management strategies can be employed to mitigate risk without necessarily discontinuing TRT:
1. Dose Reduction or Frequency Adjustment: The simplest approach is often to reduce the testosterone dose or increase the frequency of injections (e.g., from every two weeks to weekly or twice weekly). This can help lower peak testosterone levels and reduce the erythropoietic stimulus. For example, reducing a 200 mg bi-weekly injection to 100 mg weekly can often stabilize HCT.
Therapeutic Phlebotomy vs. TRT Dose Adjustment
| Feature | Therapeutic Phlebotomy | TRT Dose Adjustment/Formulation Change |
| :---------------- | :--------------------------------------------------------------- | :--------------------------------------------------------------- |
| Mechanism | Direct removal of red blood cells | Reduces erythropoietin stimulation by lowering peak testosterone |
| Effectiveness | Rapid and direct reduction of HCT | Gradual reduction, may take weeks to months |
| Side Effects | Iron deficiency, fatigue, dehydration | Potential return of hypogonadal symptoms if dose is too low |
| Convenience | Requires clinic visits for blood draw | Can be managed by patient with physician guidance |
| Cost | Varies by clinic/insurance, may be covered | Minimal additional cost, primarily medication adjustments |
Clinical Takeaway
Polycythemia, specifically erythrocytosis, is a common and manageable side effect of TRT, driven by testosterone's stimulation of erythropoietin. Regular monitoring of hematocrit (HCT) is crucial, with intervention typically considered when HCT exceeds 50-52% and TRT cessation if it reaches 54%. Management strategies include reducing testosterone dose or adjusting injection frequency, switching to a different TRT formulation (e.g., gels), or therapeutic phlebotomy. A proactive and individualized approach ensures the benefits of TRT are maintained while minimizing cardiovascular risks associated with elevated red blood cell counts.